Toshifumi Fujimori, PhD

AstraZeneca, United Kingdom

Poster(s):

• 1424 - Safety Analysis of Fixed-Duration Acalabrutinib-Venetoclax Combinations vs Chemoimmunotherapy: A Post Hoc Analysis From the Phase 3 AMPLIFY Trial